These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 35247148)
1. Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review. Fahmi AM; Elewa H; El Jilany I Int J Clin Pharm; 2022 Jun; 44(3):599-607. PubMed ID: 35247148 [TBL] [Abstract][Full Text] [Related]
2. A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional. Sridharan K; Sivaramakrishnan G J Clin Pharm Ther; 2021 Jun; 46(3):640-648. PubMed ID: 33346393 [TBL] [Abstract][Full Text] [Related]
3. Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized controlled trials. Tse G; Gong M; Li G; Wong SH; Wu WKK; Wong WT; Roever L; Lee APW; Lip GYH; Wong MCS; Liu T; Br J Clin Pharmacol; 2018 Sep; 84(9):1868-1882. PubMed ID: 29704269 [TBL] [Abstract][Full Text] [Related]
4. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis. Takeuchi M; Kobayashi T; Brandão LR; Ito S Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984 [TBL] [Abstract][Full Text] [Related]
5. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498 [TBL] [Abstract][Full Text] [Related]
6. Processes and barriers to implementation of point-of-care genotype-guided dosing of warfarin into UK outpatient anticoagulation clinics. Fitzgerald G; Prince C; Downing J; Reynolds J; Zhang JE; Hanson A; Alfirevic A; Pirmohamed M Pharmacogenomics; 2019 Jun; 20(8):599-608. PubMed ID: 31046595 [No Abstract] [Full Text] [Related]
7. Meta-analysis of randomized controlled trials reveals an improved clinical outcome of using genotype plus clinical algorithm for warfarin dosing. Liao Z; Feng S; Ling P; Zhang G J Thromb Thrombolysis; 2015 Feb; 39(2):228-34. PubMed ID: 24962733 [TBL] [Abstract][Full Text] [Related]
8. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes. Baranova EV; Verhoef TI; Ragia G; le Cessie S; Asselbergs FW; de Boer A; Manolopoulos VG; Maitland-van der Zee AH; J Thromb Haemost; 2017 Mar; 15(3):465-472. PubMed ID: 28063245 [TBL] [Abstract][Full Text] [Related]
9. A randomized trial of genotype-guided dosing of warfarin. Pirmohamed M; Burnside G; Eriksson N; Jorgensen AL; Toh CH; Nicholson T; Kesteven P; Christersson C; Wahlström B; Stafberg C; Zhang JE; Leathart JB; Kohnke H; Maitland-van der Zee AH; Williamson PR; Daly AK; Avery P; Kamali F; Wadelius M; N Engl J Med; 2013 Dec; 369(24):2294-303. PubMed ID: 24251363 [TBL] [Abstract][Full Text] [Related]
10. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. Franchini M; Mengoli C; Cruciani M; Bonfanti C; Mannucci PM J Thromb Haemost; 2014 Sep; 12(9):1480-7. PubMed ID: 25040440 [TBL] [Abstract][Full Text] [Related]
11. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. Stergiopoulos K; Brown DL JAMA Intern Med; 2014 Aug; 174(8):1330-8. PubMed ID: 24935087 [TBL] [Abstract][Full Text] [Related]
12. Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study. Sridharan K; Al Banna R; Malalla Z; Husain A; Sater M; Jassim G; Otoom S Pharmacol Rep; 2021 Oct; 73(5):1405-1417. PubMed ID: 33811620 [TBL] [Abstract][Full Text] [Related]
13. Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients. Cho SM; Lee KY; Choi JR; Lee KA Yonsei Med J; 2016 May; 57(3):635-40. PubMed ID: 26996562 [TBL] [Abstract][Full Text] [Related]
14. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Johnson JA; Caudle KE; Gong L; Whirl-Carrillo M; Stein CM; Scott SA; Lee MT; Gage BF; Kimmel SE; Perera MA; Anderson JL; Pirmohamed M; Klein TE; Limdi NA; Cavallari LH; Wadelius M Clin Pharmacol Ther; 2017 Sep; 102(3):397-404. PubMed ID: 28198005 [TBL] [Abstract][Full Text] [Related]
15. Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism. Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary OA Ir J Med Sci; 2014 Jun; 183(2):161-72. PubMed ID: 23800980 [TBL] [Abstract][Full Text] [Related]
16. Genotype-guided dosing of warfarin. Mega JL; Giugliano RP Clin Chem; 2014 Jul; 60(7):920-2. PubMed ID: 24691686 [No Abstract] [Full Text] [Related]
17. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients. Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801 [TBL] [Abstract][Full Text] [Related]
18. [Influence of warfarin related genes and non- genetic factors on administrative dose in Shanghai area]. Zhuang W; Wu D; Wang Z Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):13-7. PubMed ID: 24602724 [TBL] [Abstract][Full Text] [Related]